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Abstract Background Potential Drug–Drug Interactions
(DDI) account for many emergency department visits.
Polypharmacy, as well as herbal, over-the-counter (OTC)
and combination medication may compound this, but these
problems are not well researched in low-and-middle-in-
come countries. Objective To compare the incidence of
drug–drug interactions and polypharmacy in older and
younger patients attending the Emergency Department
(ED). Setting The adult ED of a tertiary teaching hospital in
Trinidad. Methods A 4 month cross sectional study was
conducted, comparing potential DDI in older and younger
patients discharged from the ED, as defined using Micro-
medex 2.0. Main outcome measure The incidence and
severity of DDI and polypharmacy (defined as the use of
C5 drugs simultaneously) in older and younger patients
attending the ED. Results 649 patients were included; 275
(42.3%) were C65 years and 381 (58.7%) were female.
There were 814 DDIs, of which 6 (.7%) were contraindi-
cations and 148 (18.2%) were severe. Polypharmacy was
identified in 244 (37.6%) patients. Older patients were
more likely to have potential DDI (67.5 vs 48.9%) and
polypharmacy (56 vs 24.1%). Herbal products, OTC and
combination drugs were present in 8, 36.7 and 22.2% of
patients, respectively. On multivariate analysis, polyphar-
macy and the presence of hypertension and ischaemic heart
disease were associated with an increased risk of potential
DDI. Conclusion Polypharmacy and potential drug–drug
interactions are common in ED patients in the Caribbean.
Older patients are particularly at risk, especially as they are
more likely to be on multiple medications. The association
between herbal medication and polypharmacy needs fur-
ther investigation. This study indicates the need for a more
robust system of drug reconciliation in the Caribbean.
Keywords Aged  Drug interactions  Emergency Service,
Hospital  Herb-Drug Interactions  Low-and-middle-
income country  Trinidad and Tobago
Impact on practice
• Polypharmacy and potential drug–drug interactions are
common in Emergency Department patients in
Trinidad.
• The incidence of polypharmacy and potential drug–
drug interaction problems is significantly higher in
older patients
• Potential drug–drug interactions are independently
associated with polypharmacy and the presence of
hypertension and ischaemic heart disease
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Introduction
The prevalence of drug–drug interactions (DDI) involving
prescription drugs in Emergency Department patients in
the Caribbean is not known. However, research from other
developing countries suggests that polypharmacy and
drug–drug interactions might also be common in the Car-
ibbean. Andreazza et al. [1] studied Emergency Depart-
ment (ED) patients in Brazil; one in three presented with
drug-related problems, including drug–drug interactions,
adverse drug reactions and allergic drug reactions. Al-Olah
in Saudi Arabia further concluded that 83% of the adverse
drug effects seen in Emergency Department patients were
avoidable [2]. While the demographics of some of these
countries, such as Brazil, may be similar to that seen in the
West Indies, it is unclear whether health behaviour and
prescribing are comparable [1, 3].
Polypharmacy has been identified as the single most
important risk factor for DDI [3]. There is no univer-
sally agreed definition of polypharmacy, but many
researchers describe it as the concurrent use of 5 or
more medications [4]. The risks of polypharmacy and
DDI are higher among older people, who often suffer
from a variety of medical conditions and are thus pre-
scribed multiple medications, some of which may
interact with each other to produce unwanted effects.
For example, Ruiter et al. [5] found a four-fold increase
in the risk of hospitalisation from adverse drug reac-
tions and DDIs in patients aged 75 and older compared
to those aged 55–74 years.
Researchers have demonstrated an association between
DDI, polypharmacy and acute hospital admission. A sys-
tematic review of DDI in the ED conducted by Becker
et al. [6] concluded that polypharmacy and DDIs remained
a significant cause of morbidity, particularly among older
patients. For example, Spaniolas et al. [7] showed that
older trauma patients presenting to the ED with falls were
more likely to be on multiple medications when compared
to other older trauma patients. Drug-induced cognitive
impairment, which may be exacerbated by drug–drug
interactions, is another important cause of morbidity in
older patients. This increases the chance of hospital
admission while worsening outcome [8].
Reports from Jamaica have highlighted the relatively
high prevalence of herbal medication use among hospital
patients and those with chronic illnesses, but we could not
find any Caribbean studies on polypharmacy and DDI in
Emergency Department patients [9, 10]. Our study, there-
fore, sought to investigate medication use, polypharmacy
and DDI in adults attending the ED of a large tertiary
hospital in Trinidad and Tobago, comparing older and
younger patients.
Aims of the study
The main aim of this cross-sectional study was to assess the
proportion of adult patients discharged from the ED of a
tertiary teaching hospital in Trinidad and Tobago with
polypharmacy and potential DDI, comparing patients aged
18–64 years with those aged C65 years. Secondary
objectives were to determine the association of key
demographic and clinical variables (including the use of
herbal medication) with polypharmacy and potential DDI.
Ethics approval
Ethical approval for this study was obtained from the
research ethics committee of the Faculty of Medical Sci-
ence, the University of the West Indies. Informed consent
was obtained in writing from each study participant prior to
data collection.
Methods
Data were collected prospectively over a 4 month period in
the ED of a tertiary teaching hospital. A convenience
sampling method was used, but patients were recruited
during all shifts (including night shifts) and on all days of
the week (including weekends). Data were collected using
a data collection sheet designed for the study. The main
outcomes were the presence of polypharmacy [defined as
the use of 5 or more medications, including over-the-
counter drugs (OTCs)], and the presence of potential DDI
as defined using Micromedex 2.0. When assessing
polypharmacy, OTC medications were included, and each
constituent active ingredient of any combination therapy
was counted separately. However, herbal remedies were
not counted.
All patients aged C18 years old with a Canadian Triage
Acuity Scale (CTAS) category of 2–5, who were dis-
charged from the ED after assessment and treatment, were
eligible for inclusion in the study. We focused on patients
being discharged from hospital as these were thought to be
particularly at risk; patients admitted to hospital have the
opportunity to have their medications reviewed by the
inpatient team, but discharged patients may not have any
further opportunity to have their potential drug interactions
identified and corrected, thus putting them at higher risk of
an adverse drug event.
Patients were excluded from the study if they were
admitted to hospital or were too unwell to participate (in-
cluding patients undergoing active resuscitation and those
too confused to participate). Patients who consented were
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divided into two age cohorts for comparison (18–64 years
and 65 years and older). The minimum sample size was
calculated as 276 subjects per study group (a total of 552
patients), anticipating an incidence of potential DDI of
25% (based on data from previous research), and accepting
a margin of error of 5%. The prevalence of DDI was
estimated from studies from similar (low-and-middle-in-
come country) settings as in Trinidad. It is not clear whe-
ther prescribing and health-seeking behaviours would have
been similar in these populations, but we considered these
setting the best approximation to what was likely to be
found in our study [3, 11].
Data were analysed for statistical significance using
SPSS version 21 (IBM Statistics, New York). Chi squared
analysis (or Fishers Exact Test) was used to compare the
prevalence of polypharmacy and potential DDI between
older and younger patients, using a confidence level of 95%
and a p value of .05. Logistic regression was used to
determine the association between specific covariates and
these outcomes. Covariates included in the regression
model were age; gender; ethnicity; education level; use of
over the counter (OTC) medication, herbal medication or
combined medication; polypharmacy; and the presence of
chronic illnesses (diabetes mellitus, hypertension, ischae-
mic heart disease, psychiatric illness and asthma). ‘‘Com-
bination medication’’ refers to combinations which could
include prescription and/or OTC formulations, but did not
include herbal remedies. Univariate analysis was initially
performed to determine the association between each
covariate and the outcome of interest (either polypharmacy
or potential DDI). Polypharmacy was included as a
covariate in the regression analysis for DDI. Covariates
with a moderate association with each outcome (p value
\.2) were included in the multivariate model. For the
multivariate model, a p value of\ .05 was considered as
statistically significant.
Results
There were 649 patients in the study, of which 275 were
aged C65 years and 374 were 18–64 years old. 268
(41.3%) patients were male, and 381 (58.7%) female. The
ethnicity and educational levels of the respondents are
shown in Table 1.
Polypharmacy was more common in older patients, with
154 (56%) taking 5 or more medications compared to 90
(24.1%) younger adults (p\ .001). Over the counter
medication was used by 238 (36.7%) patients, while 52
(8%) admitted to using herbal remedies, and there was no
significant difference in the use of either with age
(p = .934 for OTCs and p = .306 for herbal remedies).
Combination drugs were used in 144 (22.2%) patients, with
a higher proportion of older people using these prepara-
tions (25.1 vs 22.2%, p = .036). The specific herbal and
combination therapies reported by respondents are shown
in Appendix 1 and 2 (ESM), respectively (Table 2).
Of the 544 patients on two or more medications, 261
(48.0%) had at least one potential drug–drug interaction,
including decreased drug efficacy (due to inhibition of
absorption and distribution, as well as enhanced metabo-
lism); enhanced drug effects (due to enhanced absorption,
increased bioavailability and decreased metabolism and
excretion) and an increased risk of gastrointestinal (GI)
haemorrhage, bleeding (from sites other than the GI tract),
hypotension, thrombosis, hypoglycaemia, hyperglycaemia,
rhabdomyolysis, hyperkalaemia and lactic acidosis
(Table 3). There was a significant increase in the number of
potential DDI seen in older patients compared to younger
patients (Table 2). Of the 261 patients with potential DDI,
there were 6 (2.3%) patients on combinations of drugs that
were contraindicated. The number of patients with poten-
tial major, moderate and minor interactions as their most
serious potential DDI was 84 (32.2%), 154 (59%) and 15
(5.7%) respectively. Older patients were significantly more
likely to have more serious interactions compared to their
younger counterparts (Table 2).
In total, there were 814 potential DDIs in the 649
patients included in the study. The drugs most commonly
implicated were aspirin (281 interactions), lisinopril (114
interactions) and clopidogrel (83 interactions). The other
drugs commonly implicated in potential DDI are listed in
Table 3. Glipizide was listed in three [3] of the six con-
traindications identified. Bendrofluazide was the drug most
commonly involved in major potential interactions, while
aspirin was the drug most commonly implicated in mod-
erate potential interactions.
The multivariate logistic models for predicting
polypharmacy and potential DDI are shown in Table 4 and
5 respectively. The variables associated with an increased
risk of polypharmacy on multivariate analysis were age, the
use of OTC, herbal and combined medications, and the
presence of hypertension, ischaemic heart disease and
psychiatric illness. On univariate analysis, polypharmacy
was significantly more likely in female patients and those
with no formal education, but these associations did not
persist in the multivariate model. The variables associated
with an increased risk of potential drug–drug interaction on
multivariate analysis were polypharmacy and the presence
of hypertension and ischaemic heart disease. Asthma and
the use of combination therapies were both associated with
a decreased risk of potential DDI. The risk of potential DDI
was not influenced by age, herbal medication use or OTC
use. However, it should be noted that Micromedex 2.0 may
not have identified all potential DDIs associated with her-
bal formulations.
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Table 1 Demographic and
clinical characteristics of the
study population
Total Age C65 years Age 18–64 years All patients p value
275 374 649
Gender
Male n (%) 119 (43.3%) 149 (39.8%) 268 (41.3%) .42
Female n (%) 156 (56.7%) 225 (60.2%) 381 (58.7%)
Ethnicity
Indo-trinidadian n (%) 119 (43.3%) 129 (34.5%) 248 (38.2%) .121
Afro-trinidadian n (%) 105 (38.2%) 173 (46.3%) 278 (42.8%)
Mixed n (%) 49 (17.8%) 68 (18.2%) 117 (18%)
Other n (%) 2 (.7%) 4 (1.1%) 6 (.9%)
Education
None n (%) 16 (5.8%) 8 (2.1%) 24 (3.7%) \.001
Primary n (%) 130 (47.3%) 88 (23.5%) 218 (33.6%)
Secondary n (%) 104 (37.8%) 208 (55.6%) 312 (48.1%)
Vocational n (%) 5 (1.8%) 15 (4%) 20 (3.1%)
University n (%) 19 (6.9%) 52 (13.9%) 71 (10.9%)
Not recorded n (%) 1 (.4%) 3 (.8%) 4 (.6%)
Medical conditions
DM n (%) 121 (44%) 46 (12.3%) 167 (25.7%) \.001
HTN n (%) 153 (55.6%) 74 (19.8%) 227 (35%) \.001
IHD n (%) 54 (19.6%) 14 (3.7%) 68 (10.5%) \.001
Psych n (%) 27 (9.8%) 7 (1.9%) 34 (5.2%) \.001
Asthma n (%) 18 (6.5%) 39 (10.4%) 57 (8.8%) .055
DM diabetes mellitus, HTN hypertension, IHD ischaemic heart disease, Psych psychiatric illness
Table 2 Medication usage and
frequency of potential drug–
drug interactions
Total Age C65 years Age 18–64 years All patients p value
275 374 649
Medication usage patterns
OTC n (%) 100 (36.4%) 138 (36.9%) 238 (36.7%) .934
Herbal n (%) 18 (6.5%) 34 (9.1%) 52 (8%) .306
Combine n (%) 50 (18.2%) 94 (25.1%) 144 (22.2%) .036
Polypharmacy n (%) 154 (56%) 90 (24.1%) 244 (37.6%) \.001
Number of potential interactions seen in each patient \.001
0 n (%) 92 (33.5%) 191 (51.1%) 283 (43.6%) \.001
1–5 n (%) 53 (19.3%) 57 (15.2%) 110 (16.9%) .162
6–10 n (%) 73 (26.5%) 37 (9.9%) 110 (16.9%) \.001
[10 n (%) 35 (12.7%) 6 (1.6%) 41 (6.3%) \.001
Patients on\2 drugs n (%) 22 (8.0%) 83 (22.2%) 105 (16.2%) \.001
Most severe potential interaction seen in each patient \.001*
Contraindication n (%) 6 (3.7%) 0 (0%) .430 .430
Potential major interaction n (%) 62 (38.5%) 24 (22%) 86 (33.0%) .005
Potential moderate interaction n (%) 88 (54.7%) 66 (66%) 154 (59%) .070
Potential minor interaction n (%) 5 (3.1%) 10 (10%) 15 (5.7%) .020
Total n (%) 161 (100%) 100 (100%) 261 (100%)
* Significance calculated using fisher exact test with post hoc analysis
OTC over the counter
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Discussion
This study revealed a high percentage of patients with
potential drug–drug interactions, and many with multiple
potential interactions. Both polypharmacy and potential DDI
were more common in older patients (aged C65 years), and
there was an association between polypharmacy and the use of
herbal and over-the-counter medications. In addition, poten-
tial DDI was significantly associated with polypharmacy and
certain common chronic diseases (including hypertension,
ischaemic heart disease and psychiatric conditions).
The relationship between potential DDI, polypharmacy
and increasing age is well recognised in the research lit-
erature, and our study suggests that these associations are
also seen in Caribbean patients. Banerjee et al. [4] noted
the high rate of polypharmacy in older ED attenders in the
United Kingdom, while Hovstadius [12] (Sweden, 2006)
found a strong positive correlation between polypharmacy
and older age. Our study helps to shed some light on the
nature of the relationship between age and potential DDI:
while older people were found to have a higher incidence
of potential DDI, there was no independent association
between age and potential DDI on multivariate analysis.
However, increasing age has been associated with
polypharmacy, chronic illness and female gender in the
past, and all of these variables have also been found to be
associated with DDI in previous studies [12, 13].
Our study also highlighted a significant association
between the use of over-the-counter medication, combi-
nation therapies and herbal medication and the presence of
polypharmacy. In our multivariate model, the use of OTC
medication was associated with a five-fold increase in the
adjusted odds of polypharmacy, while patients on combi-
nation therapies had a seven-fold increase. For patients
using herbal medication, the adjusted odds of polyphar-
macy were three times that of other patients. In the Car-
ibbean, a drug history should therefore include specific
questions about herbal, OTC and combination therapies.
Table 3 Characteristics of potential drug–drug interactions
Drugs involved Severity of interaction (only commonest drugs listed) Total
Contra-
indications
Potential major
interaction
Potential moderate
interaction
Potential minor
interaction
Aspirin n (%) 0 (0%) 34 (23%) 236 (39.7%) 11 (16.4%) 281 (34.4%)
Lisinopril n (%) 0 (0%) 6 (4.1%) 99 (16.6%) 9 (13.4%) 114 (14.0%)
Clopidogrel n (%) 0 (0%) 2 (1.4%) 80 (13.4%) 1 (1.5%) 83 (10.2%)
Enalapril n (%) 0 (0%) 1 (.7%) 62 (10.4%) 0 (0%) 63 (7.7%)
Atenolol n (%) 0 (0%) 2 (1.4%) 60 (10.1%) 0 (0%) 62 (7.6%)
Bendroflumethiazide n (%) 0 (0%) 53 (35.8%) 8 (1.3%) 0 (0%) 61 (7.5%)
Glipizide n (%) 3 (50%) 8 (5.4%) 32 (5.4%) 18 (26.9%) 61 (7.5%)
Diclofenac n (%) 0 (0%) 2 (1.4%) 58 (9.7%) 0 (0%) 60 (7.4%)
Metformin n (%) 0 (0%) 5 (3.4%) 38 (6.4%) 13 (19.4%) 56 (6.9%)
Nifedipine n (%) 0 (0%) 4 (2.7%) 46 (7.7%) 1 (1.5%) 51 (6.3%)
Type of Interaction(only commonest interactions listed)
Decreased efficacy n (%) 2 (33.3%) 25 (16.9%) 291 (48.9%) 38 (56.7%) 356 (43.6%)
Enhanced effects n (%) 2 (33.3%) 18 (12.2%) 156 (26.2%) 18 (26.9%) 194 (23.8%)
Hypoglycaemia n (%) 0 11 (7.4%) 82 (13.8%) 1 (1.5%) 94 (11.5%)
Hypotension n (%) 0 4 (2.7%) 70 (11.8%) 0 (.0%) 74 (9.1%)
Hyerglycemia n (%) 0 11 (7.4%) 39 (6.6%) 0 (.0%) 50 (6.1%)
Rhabdomyolysis n (%) 1 (16.7%) 33 (22.4%) 1 (.2%) 0 (.0%) 35 (4.3%)
GI hemorrhage n (%) 0 0 (.0%) 25 (4.2%) 9 (13.4%) 34 (4.2%)
Bleeding (other) n (%) 0 62 (41.9%) 28 (4.7%) 1 (1.5%) 91 (11.2%)
Thrombosis n (%) 0 22 (14.8%) 2 (3.3%) 0 (.0%) 24 (2.9%)
Hyperkalemia n (%) 0 6 (4.1%) 10 (1.7%) 0 (.0%) 16 (2.0%)
Lactic acidosis n (%) 0 0 (.0%) 16 (2.7%) 0 (.0%) 16 (2.0%)
Total n (%) 6 (100%) 148 (100%) 595 (100%) 67 (100%) 814 (100%)
Only the commonest drugs and interactions are listed
GI gastro-intestinal
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Interestingly, there was no significant association
between the use of OTC, herbal or combination therapies
and the risk of potential DDI. In fact, on multivariate
analysis, the odds of potential DDI in patients using com-
bination therapies was actually less than for other patients.
It is not clear why the association between these therapies
and polypharmacy did not translate to an increased risk of
potential DDI. This may have been due to the confounding
effects of other demographic variables, such as age and the
presence of chronic illnesses. It should be noted, however,
that our study was not specifically powered to detect any
differences in potential DDIs in patients on OTCs,
combination therapies or herbal formulations. As discussed
earlier, previous work in Jamaica highlighted the associa-
tion between herbal medication, polypharmacy and
potential DDI in diabetic patients [9, 10]. Similar associ-
ations may also exist in other patients with chronic ill-
nesses, such as ischaemic heart disease and hypertension.
The significant association between common chronic
illnesses such as ischaemic heart disease, hypertension and
diabetes and potential DDI is not unexpected, given that
these patients were more likely to be on multiple drugs. In
addition to this, 11 of the top 12 drugs most commonly
implicated in potential DDI were prescribed for these
Table 4 Multivariate logistic regression analysis of factors associated with polypharmacy
No. of patients (%) Univariate analysis Multivariate analysis
No
Polypharmacy
Polypharmacy Unadjusted odds
ratio
95% C.I. p value Adjusted odds
ratio
95% C.I. p value
Lower Upper Lower Upper
Age
18–64 284 (75.9%) 90 (24.1%) Reference
C65 121 (44%) 154 (56%) 4.016 2.870 5.620 \.001 2.373 1.435 3.923 .001
Gender
Male 180 (67.2%) 88 (32.8%) Reference
Female 225 (59.1%) 156 (40.9%) 1.418 1.023 1.966 .036 .992 .624 1.576 .972
Ethnicity
Indo-
trinidadian
146 (58.9%) 102 (41.1%) Reference
Afro-
trinidadian
181 (65.1%) 97 (34.9%) .767 .539 1.092 .141
Mixed 74 (63.2%) 43 (36.8%) .832 .529 1.308 .425
Other 4 (66.7%) 2 (33.3%) .716 .129 3.981 .702
Education
None 6 (25%) 18 (75%) Reference
Primary 118 (54.1%) 100 (45.9%) .282 .108 .739 .010 .297 .075 1.174 .083
Secondary 217 (69.6%) 95 (30.4%) .146 .056 .379 \.001 .314 .081 1.221 .095
Vocational 11 (55%) 9 (45%) .273 .076 .978 .046 1.196 .209 6.834 .840
University 51 (71.8%) 20 (28.2%) .131 .045 .377 .000 .255 .057 1.145 .075
Not
recorded
2 (50%) 2 (50%) .333 .038 2.910 .320 2.535 .106 60.427 .565
Medical formulation
OTC 107 (45%) 131 (55%) 3.229 2.310 4.513 \.001 5.243 3.212 8.559 \.001
Herbal 25 (48.1%) 27 (51.9%) 1.891 1.071 3.341 .028 3.608 1.649 7.896 .001
Combination 63 (43.8%) 81 (56.3%) 2.698 1.848 3.938 \.001 7.590 4.317 13.347 \.001
Chronic illness
DM 55 (32.9%) 112 (67.1%) 5.399 3.693 7.894 \.001 4.499 2.589 7.817 \.001
HTN 68 (30%) 159 (70%) 9.270 6.400 13.427 \.001 7.227 4.316 12.101 \.001
IHD 10 (14.7%) 58 (85.3%) 12.317 6.157 24.640 \.001 7.774 3.294 18.348 \.001
Psych 7 (20.6%) 27 (79.4%) 7.074 3.031 16.512 \.001 4.341 1.428 13.201 .010
Asthma 32 (56.1%) 25 (43.9%) 1.331 .768 2.304 .308
Each ‘medical formulation’ and ‘chronic illness’ was treated as an independent covariate in the equation; for each of these variables, patients
without the variable were used as the reference
OTC over the counter, DM diabetes mellitus, HTN hypertension, IHD ischaemic heart disease
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conditions. Of these drugs, aspirin, bendrofluazide, glip-
izide, lisinopril and diltiazem accounted for the majority of
major potential interactions and contraindications. This
emphasizes the importance of drug reconciliation in
patients with common chronic illnesses who present to the
Emergency Department. In contrast, it is likely that the
decrease in potential DDI with asthma was because the
drug combinations used in asthma follow the GINA
(Global Initiative on Asthma) guidelines, which would
avoid the risk of potential DDI. In general, these guidelines
are adhered to in the Caribbean, due to their high profile in
public health campaigns on asthma [14].
While this study provides an important insight into the
use of medication in patients in a low-and-middle-income
country setting, there were a few limitations. As a single
centre study, there was a risk of selection bias. However,
Eric Williams Medical Sciences Complex serves approxi-
mately half of the population of Trinidad and Tobago, and
census reports from the hospital suggest that the patients
attending the ED are broadly representative of the ethnic
Table 5 Multivariate logistic regression analysis of factors associated with potential drug–drug interactions (DDI)
No. of patients (%) Univariate analysis Multivariate analysis
No potential
DDI
Potential
DDI
Unadjusted odds
ratio
95% C.I. p value Adjusted odds
ratio
95% C.I. p value
Lower Upper Lower Upper
Age
18–64 191 (65.6%) 100 (34.4%) Reference
[=65 92 (36.4%) 161 (63.6%) 3.342 2.350 4.754 \.001 1.222 .758 1.972 .409
Gender
Male 122 (56.7%) 93 (43.3%) Reference
Female 161 (48.9%) 168 (51.1%) 1.369 .969 1.934 .075 1.543 .987 2.412 .057
Ethnicity
Indo-
trinidadian
109 (51.9%) 101 (48.1%) Reference
Afro-
trinidadian
118 (51.3%) 112 (48.7%) 1.024 .704 1.489 .900
Mixed 54 (53.5%) 47 (46.5%) .939 .584 1.511 .796
Other 2 (66.7%) 1 (33.3%) .540 .048 6.042 .617
Education
None 7 (30.4%) 16 (69.6%) Reference
Primary 82 (42.3%) 112 (57.7%) .598 .235 1.519 .279 .869 .269 2.814 .815
Secondary 153 (60.5%) 100 (39.5%) .286 .114 .720 .008 .717 .224 2.298 .575
Vocational 10 (58.8%) 7 (41.2%) .306 .082 1.137 .077 .886 .176 4.452 .883
University 30 (54.5%) 25 (45.5%) .365 .130 1.026 .056 1.329 .362 4.881 .668
Not recorded 1 (50%) 1 (50%) .438 .024 8.036 .578 .281 .004 20.309 .561
Medical formulation
OTC 102 (47.7%) 112 (52.3%) 1.334 .945 1.883 .102 .790 .485 1.288 .345
Herbal 28 (56%) 22 (44%) .838 .467 1.506 .555 .710 .320 1.577 .401
Combination 83 (58.5%) 59 (41.5%) .704 .478 1.036 .075 .533 .309 .919 .024
Polypharmacy 59 (24.2%) 185 (75.8%) 9.242 6.245 13.676 \.001 6.392 3.691 11.069 .000
Chronic illness
DM 45 (27.8%) 117 (72.2%) 4.297 2.877 6.419 \.001 1.442 .842 2.469 .182
HTN 47 (21.3%) 174 (78.7%) 10.043 6.696 15.061 \.001 3.972 2.437 6.473 \.001
IHD 8 (11.8%) 60 (88.2%) 10.261 4.800 21.937 \.001 3.633 1.477 8.938 .005
Psych 6 (18.2%) 27 (81.8%) 5.327 2.162 13.123 \.001 2.514 .851 7.429 .095
Asthma 35 (71.4%) 14 (28.6%) .402 .211 .765 \.001 .350 .152 .807 .014
Each ‘medical formulation’ and ‘chronic illness’ was treated as an independent covariate in the equation; for each of these variables, patients
without the variable were used as the reference
OTC over the counter, DM diabetes mellitus, HTN hypertension, IHD ischaemic heart disease
Int J Clin Pharm
123
and demographic make-up of the population as a whole.
There was a risk of under-reporting of medication by study
participants. While data was collected prospectively to
minimise this, no attempt was made to verify patients’
accounts of their medication usage (such as checking drug
dispensers or cross referencing with relatives and carers).
Thus, we could not comment on whether patients were
compliant with their medication, an important factor when
considering potential DDI. In addition, Micromedex 2.0
did not list all the herbal medications found in our study, so
any potential interactions involving these unlisted herbal
remedies would have been missed. This may have con-
tributed to the lack of association between herbal formu-
lations and potential DDI, as may have the inadequate
sample size of patients aged C65 years. This small sample
size (which, for the older cohort of patients, was just under
the calculated sample size of 276 patients) may also have
contributed to some of the other statistically insignificant
findings of this study, such as the lack of association
between age, OTCs and potential drug–drug interactions.
As mentioned in the ‘‘Methods’’ section, this study
focused on ED patients who were discharged from the
department, as we were interested in the number of patients
with potential DDIs who were being discharged with
potentially no further follow up. However, the results do
not tell us anything about the level of polypharmacy and
potential DDIs in patients who were admitted. It may
reasonably be surmised that these patients could have had a
higher risk of polypharmacy and potential DDI as they
were more unwell than those discharged home and there-
fore more likely to be on multiple medications.
As a result of our study, we intend to develop and assess
programmes targeted at older ED attenders, including ED
rounds with clinical pharmacists; implementation of a drug
reconciliation service (involving the assessment of all
patients aged C65 years on 5 or more medications by a
clinical pharmacist and senior doctor prior to discharge);
training doctors in safe prescribing practices in older
patients and targeted health education campaigns.
Conclusion
This study has identified a high level of polypharmacy and
potential drug–drug interactions in patients attending the
Emergency Department in Trinidad and Tobago, high-
lighting important risk factors that may predict these out-
comes (including increasing age, chronic illnesses, and the
use of herbal, combination and OTC remedies). Specifi-
cally, while OTC, increased age and herbal medications
were all independently associated with an increased risk of
polypharmacy, the only factors predictive of potential
drug–drug interactions were polypharmacy and common
chronic illnesses (diabetes, hypertension and ischaemic
heart disease). Targeted initiatives aimed at older people
and those with chronic illnesses are therefore likely to
reduce the risk of polypharmacy and potential DDI in this
setting.
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